for people ages 18 years and up (full criteria)
study started
estimated completion



CC-90002-ST -001 is an open-label, Phase 1, dose escalation and expansion clinical study in subjects advanced, refractory solid and hematologic cancers.

Official Title

A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers


CC-90002-ST-001 is an open-label, Phase 1, dose escalation and expansion, first in human (FIH) clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with advanced, refractory solid and hematologic cancers.

The study will be conducted in two parts. Part A dose escalation phase will explore escalating dose cohorts of the study drug CC-90002.

Part B dose escalation will explore escalating doses of CC-90002 in combination with rituximab and expansion in combination with rituximab in subjects with CD20-positive NHL.


Hematologic Neoplasms CC-90002 Monoclonal Antibody CD47 Advanced Solid Cancers Hematologic Cancers Rituximab


You can join if…

Open to people ages 18 years and up

  1. Men and women, 18 years or older, with advanced, relapsed or refractory solid tumors, Multiple Myeloma (MM) or non-Hodgkin's lymphoma (NHL) in Part A. In Part B, relapsed and/or refractory CD20-positive NHL subjects only.
  2. At least one site of measurable disease in subjects with solid tumors and NHL.
  3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  4. Subjects must have adequate hematopoietic, liver, renal and coagulation function as assessed by specific laboratory criteria.
  5. Females and males must agree to contraceptive methods and avoid conceiving throughout the study, and for up to 8 weeks following the last dose of CC-90002. If participating in Part B, females of child bearing potential should continue to use effective contraceptive methods for 12 months following treatment with rituximab

You CAN'T join if...

  1. High grade lymphomas (Burkitts or lymphoblastic), plasma cell leukemia.
  2. High grade, rapidly proliferative solid tumors (eg, small cell lung cancer, germ cell tumors, neuroblastoma) with extensive tumor burden.
  3. Symptomatic central nervous system involvement.
  4. Impaired cardiac function or clinically significant cardiac disease.
  5. Prior Red blood cell (RBC) transfusion < 3 months prior to starting CC-90002 (Part A only).
  6. Prior autologous stem cell transplant ≤ 3 months prior to starting CC-90002.
  7. Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-90002.
  8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting CC-90002, whichever is shorter.
  9. Major surgery ≤ 2 weeks prior to starting CC-90002.
  10. . Pregnant or nursing females.
  11. . Known HIV infection.
  12. . Known chronic, active hepatitis B or C (HBV/HCV) infection.
  13. . Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.
  14. . History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
  15. . History of concurrent second cancers requiring active, ongoing systemic treatment.

concurrent second cancers requiring active, ongoing systemic treatment.


  • University of California San Francisco
    San Francisco California 94143 United States
  • Scottsdale Healthcare Research Institute
    Scottsdale Arizona 85258 United States


in progress, not accepting new patients
Start Date
Completion Date
Phase 1
Study Type
Last Updated